EasySep™人Pan-CD25正选和去除试剂盒

免疫磁珠正选细胞分选试剂盒

产品号 #(选择产品)

产品号 #17861_C

免疫磁珠正选细胞分选试剂盒

产品优势

  • 操作简单、快捷,且无需分离柱
  • CD25+细胞的去除率高达3个对数级
  • 纯度高达98%

产品组分包括

  • EasySep™ 人Pan-CD25正选和去除试剂盒(产品号 #17861)
    • EasySep™ 人Pan-CD25正选和去除抗体混合物,1 mL
    • EasySep™ Dextran RapidSpheres™ 50100 磁珠,2 x 1 mL
New look, same high quality and support! You may notice that your instrument or reagent packaging looks slightly different from images displayed on the website, or from previous orders. We are updating our look but rest assured, the products themselves and how you should use them have not changed. Learn more

总览

EasySep™ 人Pan-CD25正选和去除试剂盒专为从人新鲜外周血单个核细胞(PBMCs)或裂解的白细胞单采术样本中去除CD25+细胞而设计。目的细胞被识别CD25的抗体四聚体复合物和葡聚糖包被的磁珠标记,通过EasySep™磁极进行无柱分选,标记的细胞保留在分离管中,未被标记的细胞倒出即可。CD25抗原通常表达于调节性T细胞及活化的T、B细胞表面。

磁体兼容性
• EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001)
 
亚型
细胞分选试剂盒
 
细胞类型
T 细胞,CD4+,T 细胞,调节性细胞
 
种属

 
样本来源
PBMC
 
筛选方法
删除
 
应用
细胞分选
 
品牌
EasySep
 
研究领域
免疫
 

Data Figures

CD25 cell depletion results using EasySep™

Starting with fresh PBMCs, the CD25+ cell content of the depleted fraction typically ranges from 2 - 5%. In the above example, the purities of the start and final depleted fractions are 14.5% and 2.2%, respectively, with a 1.3 log depletion of CD25+ cells. Using the optional positive selection protocol, the CD25+ cell content of the isolated fraction typically ranges from 81 - 98% (data not shown).

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
17861
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
17861
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
17861
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (9)

Publications (2)

CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer's PSEN2 N141I neurons. M. Ortiz-Virumbrales et al. Acta neuropathologica communications 2017 dec

Abstract

Basal forebrain cholinergic neurons (BFCNs) are believed to be one of the first cell types to be affected in all forms of AD, and their dysfunction is clinically correlated with impaired short-term memory formation and retrieval. We present an optimized in vitro protocol to generate human BFCNs from iPSCs, using cell lines from presenilin 2 (PSEN2) mutation carriers and controls. As expected, cell lines harboring the PSEN2 N141I mutation displayed an increase in the A$\beta$42/40 in iPSC-derived BFCNs. Neurons derived from PSEN2 N141I lines generated fewer maximum number of spikes in response to a square depolarizing current injection. The height of the first action potential at rheobase current injection was also significantly decreased in PSEN2 N141I BFCNs. CRISPR/Cas9 correction of the PSEN2 point mutation abolished the electrophysiological deficit, restoring both the maximal number of spikes and spike height to the levels recorded in controls. Increased A$\beta$42/40 was also normalized following CRISPR/Cas-mediated correction of the PSEN2 N141I mutation. The genome editing data confirms the robust consistency of mutation-related changes in A$\beta$42/40 ratio while also showing a PSEN2-mutation-related alteration in electrophysiology.
Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation. Albert BJ et al. Scientific reports 2017 AUG

Abstract

Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus. Elimination of these reservoirs through the administration of synergistic combinations of latency reversing agents (LRAs), such as histone deacetylase (HDAC) inhibitors and protein kinase C (PKC) modulators, provides a promising strategy to reduce if not eradicate the viral reservoir. Here, we demonstrate that largazole and its analogues are isoform-targeted histone deacetylase inhibitors and potent LRAs. Significantly, these isoform-targeted HDAC inhibitors synergize with PKC modulators, namely bryostatin-1 analogues (bryologs). Implementation of this unprecedented LRA combination induces HIV-1 reactivation to unparalleled levels and avoids global T-cell activation within resting CD4+ T-cells.

更多信息

更多信息
Species Human
Magnet Compatibility • EasySep™ Magnet (Catalog #18000) • “The Big Easy” EasySep™ Magnet (Catalog #18001)
Sample Source PBMC
Selection Method Depletion
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。